-DOCSTART- -X- O
The -X- _ O
promise -X- _ O
of -X- _ O
nucleic -X- _ O
acid -X- _ O
based -X- _ O
oligonucleotides -X- _ O
as -X- _ O
effective -X- _ O
genetic -X- _ O
therapies -X- _ O
has -X- _ O
been -X- _ O
held -X- _ O
back -X- _ O
by -X- _ O
their -X- _ O
low -X- _ O
bioavailability -X- _ O
and -X- _ O
poor -X- _ O
cellular -X- _ B-Intervention
uptake -X- _ I-Intervention
to -X- _ O
target -X- _ O
tissues -X- _ O
upon -X- _ O
systemic -X- _ O
administration. -X- _ O
One -X- _ O
such -X- _ O
strategy -X- _ O
to -X- _ O
improve -X- _ O
upon -X- _ O
delivery -X- _ O
is -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
short -X- _ B-Intervention
cell-penetrating -X- _ I-Intervention
peptides -X- _ I-Intervention
( -X- _ I-Intervention
CPPs -X- _ I-Intervention
) -X- _ I-Intervention
that -X- _ O
can -X- _ O
be -X- _ O
either -X- _ O
directly -X- _ O
attached -X- _ O
to -X- _ O
their -X- _ O
cargo -X- _ O
through -X- _ O
covalent -X- _ B-Intervention
linkages -X- _ I-Intervention
or -X- _ O
through -X- _ O
the -X- _ O
formation -X- _ O
of -X- _ O
noncovalent -X- _ B-Intervention
nanoparticle -X- _ I-Intervention
complexes -X- _ I-Intervention
that -X- _ O
can -X- _ O
facilitate -X- _ O
cellular -X- _ B-Intervention
uptake. -X- _ I-Intervention
In -X- _ O
this -X- _ O
review -X- _ O
, -X- _ O
we -X- _ O
will -X- _ O
highlight -X- _ O
recent -X- _ O
proof-of-principle -X- _ B-Intervention
studies -X- _ I-Intervention
that -X- _ O
have -X- _ O
utilized -X- _ O
both -X- _ O
of -X- _ O
these -X- _ O
strategies -X- _ O
to -X- _ O
improve -X- _ O
nucleic -X- _ B-Outcome
acid -X- _ I-Outcome
delivery -X- _ I-Outcome
and -X- _ O
discuss -X- _ O
the -X- _ O
prospects -X- _ O
for -X- _ O
translation -X- _ O
of -X- _ O
this -X- _ O
approach -X- _ O
for -X- _ O
clinical -X- _ B-Outcome
application -X- _ I-Outcome
. -X- _ O

